Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) and Neurogene (NASDAQ:NGNE – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.
Institutional & Insider Ownership
60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 4.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 11.6% of Neurogene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Aligos Therapeutics and Neurogene”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aligos Therapeutics | $3.94 million | 15.59 | -$131.21 million | ($19.76) | -0.51 |
| Neurogene | $930,000.00 | 337.78 | -$75.14 million | ($4.11) | -4.93 |
Neurogene has lower revenue, but higher earnings than Aligos Therapeutics. Neurogene is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and price targets for Aligos Therapeutics and Neurogene, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aligos Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
| Neurogene | 1 | 2 | 4 | 0 | 2.43 |
Aligos Therapeutics currently has a consensus target price of $50.00, indicating a potential upside of 400.50%. Neurogene has a consensus target price of $42.50, indicating a potential upside of 109.57%. Given Aligos Therapeutics’ higher possible upside, research analysts clearly believe Aligos Therapeutics is more favorable than Neurogene.
Profitability
This table compares Aligos Therapeutics and Neurogene’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aligos Therapeutics | -3,267.65% | -39.35% | -22.09% |
| Neurogene | N/A | -29.84% | -27.55% |
Volatility & Risk
Aligos Therapeutics has a beta of 2.74, meaning that its stock price is 174% more volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500.
Summary
Neurogene beats Aligos Therapeutics on 8 of the 14 factors compared between the two stocks.
About Aligos Therapeutics
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
About Neurogene
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
